Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
5,400
Employees5,400
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
5,400
Employees5,400

PODD Key Statistics

Market cap
11.06B
Market cap11.06B
Price-Earnings ratio
35.26
Price-Earnings ratio35.26
Dividend yield
Dividend yield
Average volume
1.79M
Average volume1.79M
High today
$162.00
High today$162.00
Low today
$149.17
Low today$149.17
Open price
$150.92
Open price$150.92
Volume
1.82M
Volume1.82M
52 Week high
$354.88
52 Week high$354.88
52 Week low
$140.63
52 Week low$140.63

Stock Snapshot

As of today, Insulet(PODD) shares are valued at $162.00. The company's market cap stands at 11.06B, with a P/E ratio of 35.26.

During the trading session on 2026-06-10, Insulet(PODD) shares reached a daily high of $162.00 and a low of $149.17. At a current price of $162.00, the stock is +8.6% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 1.82M, compared to an average daily volume of 1.79M.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $140.63.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $140.63.

PODD News

MarketWatch 1d
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch

...

Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Nasdaq 1d
Monday 6/8 Insider Buying Report: PODD, ADC

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably...

Monday 6/8 Insider Buying Report: PODD, ADC
TipRanks 2d
Insulet announces new results on tubeless AID systems

Insulet (PODD) announced new clinical results highlighting the “next breakthroughs” in tubeless Automated Insulin Delivery, AID, systems. The data and growing b...

Analyst ratings

89%

of 27 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

More PODD News

Simply Wall St 3d
Assessing Insulet Valuation After New Omnipod 6 And Closed Loop Diabetes Data

Insulet (PODD) just released new clinical data on its future Omnipod 6 and fully closed loop systems, showing improved glucose control across type 1 and type 2...

Assessing Insulet Valuation After New Omnipod 6 And Closed Loop Diabetes Data
TipRanks 5d
CDRH issues Early Alert about pump issue from Insulet

The FDA is aware that Insulet (PODD) has issued a letter to affected customers recommending certain Omnipod Pods be removed from where they are used or sold, th...

Nasdaq 6d
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

Key Points DexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries. Insulet dominates the tubele...

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
TipRanks 6d
Insulet announces planned activities during ADA Scientific Sessions

Insulet (PODD) announced its planned activities during the American Diabetes Association, ADA, 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Or...

TipRanks 7d
Insulet announces U.S. rollout of enhanced Omnipod 5 algorithm

Insulet (PODD) Corporation announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery, AID, System. The updates follo...

Simply Wall St 7d
Insulet Is Down 7.4% After Major Omnipod Pod Recall Exposes Manufacturing Defect Risk

In late May 2026, Insulet announced a voluntary medical device correction covering about 7 million Omnipod Pods after detecting a manufacturing defect that can...

Insulet Is Down 7.4% After Major Omnipod Pod Recall Exposes Manufacturing Defect Risk

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.